TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?

It has been about a month since the last earnings report for TG Therapeutics (TGTX). Shares have added about 15.1% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is TG Therapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.

TG Therapeutics Q2 Earnings Lag, Sales Rise Y/Y, 2026 View Raised

TG Therapeutics reported earnings of 5 cents per share for the second quarter of 2026, missing the Zacks Consensus Estimate of 41 cents. The company had reported earnings of 17 cents per share in the year-ago quarter.

Total revenues in the second quarter were $240.3 million, up almost 70.3% year over year, driven by strong demand for the company’s sole marketed drug, Briumvi. The figure beat the Zacks Consensus Estimate of $231 million.

Quarter in Detail

The top line comprised product sales from Briumvi and license, royalty and other revenues.

Total product revenues were $235.8 million in the reported quarter, reflecting a 69.9% year-over-year increase. Total product revenues included sales of Briumvi to TG Therapeutics’ licensing partner, Neuraxpharm, in ex-U.S. markets, of $8.1 million.

Briumvi's net product sales in the United States were $227.7 million in the second quarter, up 64% year over year. Sales of the drug came in ahead of management’s guided range of $220 million.

License, milestone, royalty and other revenues were $4.5 million in the second quarter, compared with $2.3 million reported in the year-ago quarter.

Research and development (R&D) expenses (excluding stock-based compensation) surged 217.5% year over year to $87.3 million due to higher expenses related to ongoing clinical studies.

Selling, general and administrative (SG&A) expenses (excluding stock-based compensation) totaled $62.3 million, up 43.2% from the year-ago quarter’s level, due to higher commercialization costs for Briumvi as well as other personnel costs.

As of June 30, 2026, TG Therapeutics had cash, cash equivalents and investments worth $612.3 million compared with $572.8 million as of March 31, 2026.

2026 Guidance

TG Therapeutics raised its total revenue guidance.

The company now expects worldwide total revenues of around $950 million in 2026, compared with the previous expectation of around $925 million.

The company now expects net product revenues of $890-$905 million from Briumvi sales in the United States in 2026, up from the previous expectation of $885-$900 million.

Excluding non-cash compensation, total operating expenses, defined as R&D and SG&A, are now expected to be around $350-$400 million in 2026, compared with the previous expectation of around $350 million.

How Have Estimates Been Moving Since Then?

It turns out, estimates revision have trended downward during the past month.

VGM Scores

At this time, TG Therapeutics has a poor Growth Score of F, a grade with the same score on the momentum front. Charting a somewhat similar path, the stock was allocated a score of D on the value side, putting it in the bottom 40% for this investment strategy.

Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.

Outlook

Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, TG Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry Player

TG Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Alnylam Pharmaceuticals (ALNY), a stock from the same industry, has gained 12.4%. The company reported its results for the quarter ended June 2026 more than a month ago.

Alnylam reported revenues of $1.29 billion in the last reported quarter, representing a year-over-year change of +66.9%. EPS of $1.84 for the same period compares with $0.32 a year ago.

For the current quarter, Alnylam is expected to post earnings of $2.19 per share, indicating a change of -24.5% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.7% over the last 30 days.

Alnylam has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of C.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research